These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 23679074

  • 21. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.
    Rodríguez-Tajes S, Miralpeix A, Costa J, López-Suñé E, Laguno M, Pocurull A, Lens S, Mariño Z, Forns X.
    J Viral Hepat; 2021 Jan; 28(1):89-94. PubMed ID: 32969557
    [Abstract] [Full Text] [Related]

  • 22. Impact of Hepatitis B Surface and Core Antibody Levels on Hepatitis B Virus Reactivation.
    Ohkubo M, Seo E, Doki K, Suzuki Y, Sekine I, Homma M.
    Biol Pharm Bull; 2024 Jan; 47(5):941-945. PubMed ID: 38735754
    [Abstract] [Full Text] [Related]

  • 23. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.
    Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lau EHY, Cheung KS, Lie AKW, Lai CL, Kwong YL, Yuen MF.
    Hepatology; 2017 May; 65(5):1451-1461. PubMed ID: 28027590
    [Abstract] [Full Text] [Related]

  • 24. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW.
    Clin Transplant; 2006 May; 20(3):369-73. PubMed ID: 16824156
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
    Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, Burmester G, Walls C, Wu WS, Dickson C, Liao R, Genovese MC.
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
    [Abstract] [Full Text] [Related]

  • 26. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW, Coyle L, Jones BE, Pattullo V.
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [Abstract] [Full Text] [Related]

  • 27. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.
    Salpini R, Colagrossi L, Bellocchi MC, Surdo M, Becker C, Alteri C, Aragri M, Ricciardi A, Armenia D, Pollicita M, Di Santo F, Carioti L, Louzoun Y, Mastroianni CM, Lichtner M, Paoloni M, Esposito M, D'Amore C, Marrone A, Marignani M, Sarrecchia C, Sarmati L, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V.
    Hepatology; 2015 Mar; 61(3):823-33. PubMed ID: 25418031
    [Abstract] [Full Text] [Related]

  • 28. Pre-transplant donor HBV DNA+ and male recipient are independent risk factors for treatment failure in HBsAg+ donors to HBsAg- kidney transplant recipients.
    Wang XD, Feng SJ, Liu JP, Song TR, Huang ZL, Fan Y, Shi YY, Chen LY, Lv YH, Xu ZL, Li XH, Wang L, Lin T.
    BMC Infect Dis; 2021 Jan 09; 21(1):41. PubMed ID: 33422017
    [Abstract] [Full Text] [Related]

  • 29. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
    Ueda Y, Marusawa H, Egawa H, Okamoto S, Ogura Y, Oike F, Nishijima N, Takada Y, Uemoto S, Chiba T.
    Antivir Ther; 2011 Jan 09; 16(4):479-87. PubMed ID: 21685535
    [Abstract] [Full Text] [Related]

  • 30. Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation.
    Duhart BT, Honaker MR, Shokouh-Amiri MH, Riely CA, Vera SR, Taylor SL, Al-jedai AH, Gaber AO.
    Transpl Infect Dis; 2003 Sep 09; 5(3):126-31. PubMed ID: 14617300
    [Abstract] [Full Text] [Related]

  • 31. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention.
    Sagnelli C, Pisaturo M, Calò F, Martini S, Sagnelli E, Coppola N.
    World J Gastroenterol; 2019 Jul 14; 25(26):3299-3312. PubMed ID: 31341357
    [Abstract] [Full Text] [Related]

  • 32. Hepatitis B virus infection status is an independent risk factor for multiple myeloma patients after autologous hematopoietic stem cell transplantation.
    Li J, Liu J, Huang B, Zheng D, Chen M, Zhou Z, Xu D, Zou W.
    Tumour Biol; 2013 Jun 14; 34(3):1723-8. PubMed ID: 23436046
    [Abstract] [Full Text] [Related]

  • 33. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving immunosuppressive therapy for glomerulonephritis: a retrospective analysis.
    Fang J, Li W, Peng X, Tan Z, Tan M, Zhang C, Wang W, Xu Z, Zhou G.
    Int Urol Nephrol; 2017 Mar 14; 49(3):475-482. PubMed ID: 28032257
    [Abstract] [Full Text] [Related]

  • 34. Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy.
    Gao N, Yu H, Zhang J, Mo Z, Chu J, Xie C, Peng L, Gao Z.
    J Viral Hepat; 2022 Oct 14; 29(10):899-907. PubMed ID: 35871534
    [Abstract] [Full Text] [Related]

  • 35. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
    Buzo BF, Ramos JF, Marques Rossetti RA, Salles N, Mendrone-Júnior A, Rocha V, de Seixas Santos Nastri AC.
    Transpl Infect Dis; 2020 Apr 14; 22(2):e13243. PubMed ID: 31901206
    [Abstract] [Full Text] [Related]

  • 36. Lamivudine treatment in a patient with hepatitis B virus reactivation after allogenic peripheral bone marrow transplantation.
    Imamura T, Yokosuka O, Chiba T, Kanda T, Kojima H, Fukai K, Imazeki F, Nishimura M, Saito Y, Saisho H.
    Leuk Lymphoma; 2005 Jun 14; 46(6):915-7. PubMed ID: 16019538
    [Abstract] [Full Text] [Related]

  • 37. The difficulties of managing severe hepatitis B virus reactivation.
    Roche B, Samuel D.
    Liver Int; 2011 Jan 14; 31 Suppl 1():104-10. PubMed ID: 21205146
    [Abstract] [Full Text] [Related]

  • 38. Complete hepatitis B virus prophylaxis withdrawal in hepatitis B surface antigen-positive liver transplant recipients after longterm minimal immunosuppression.
    Lenci I, Baiocchi L, Tariciotti L, Di Paolo D, Milana M, Santopaolo F, Manzia TM, Toti L, Svicher V, Tisone G, Perno CF, Angelico M.
    Liver Transpl; 2016 Sep 14; 22(9):1205-13. PubMed ID: 27272189
    [Abstract] [Full Text] [Related]

  • 39. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma.
    Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M.
    BMC Gastroenterol; 2014 Feb 17; 14():31. PubMed ID: 24533834
    [Abstract] [Full Text] [Related]

  • 40. Roles of Hepatitis B Virus Mutations in the Viral Reactivation after Immunosuppression Therapies.
    Inoue J, Nakamura T, Masamune A.
    Viruses; 2019 May 19; 11(5):. PubMed ID: 31109119
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.